XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited - USD ($)
$ in Thousands
Total
Class A Common Stock
Class B Common Stock
Redeemable Noncontrolling Interest
Redeemable Noncontrolling Interest
Common Stock
Class A Common Stock
Common Stock
Class B Common Stock
Note Receivable for Common Stock
Note Receivable for Common Stock
Class A Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Class A Common Stock
Accumulated Deficit
Beginning balance at Dec. 31, 2021       $ 24,962              
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss       (4,564)              
Change in redemption value of noncontrolling interest       3,809              
Ending balance at Sep. 30, 2022       24,207              
Beginning balance, shares (in shares) at Dec. 31, 2021         66,942,777 23,093,860          
Beginning balance at Dec. 31, 2021 $ (9,740)       $ 669 $ 232 $ 0   $ 238,193   $ (248,834)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (14,419)                   (14,419)
Share-based compensation 981               981    
Issuance of Class A Common Stock to Collaboration Partner (in shares)         10,386,274            
Issuance of Class A common stock to collaboration partner, net of offering cost 5,040       $ 104         $ 4,936  
Issuance of Class A common stock under CinRx purchase agreement, net of offering costs (in shares)         4,154,549            
Issuance of Class A common stock under CinRx purchase agreement, net of offering costs 5,378       $ 42     $ (4,000)   9,336  
Change in redemption value of noncontrolling interest (3,809)                   (3,809)
Ending balance, shares (in shares) at Sep. 30, 2022         81,483,600 23,093,860          
Ending balance at Sep. 30, 2022 (16,569)       $ 815 $ 232 (4,000)   253,446   (267,062)
Beginning balance at Jun. 30, 2022       15,916              
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss       (1,207)              
Change in redemption value of noncontrolling interest       9,498              
Ending balance at Sep. 30, 2022       24,207              
Beginning balance, shares (in shares) at Jun. 30, 2022         77,329,051 23,093,860          
Beginning balance at Jun. 30, 2022 (8,526)       $ 773 $ 232 0   243,772   (253,303)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (4,261)                   (4,261)
Share-based compensation 338               338    
Issuance of Class A common stock under CinRx purchase agreement, net of offering costs (in shares)         4,154,549            
Issuance of Class A common stock under CinRx purchase agreement, net of offering costs 5,378       $ 42     $ (4,000)   $ 9,336  
Change in redemption value of noncontrolling interest (9,498)                   (9,498)
Ending balance, shares (in shares) at Sep. 30, 2022         81,483,600 23,093,860          
Ending balance at Sep. 30, 2022 (16,569)       $ 815 $ 232 $ (4,000)   253,446   (267,062)
Beginning balance at Dec. 31, 2022 16,579     16,579              
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss       (4,753)              
Change in redemption value of noncontrolling interest       (1,104)              
Ending balance at Sep. 30, 2023 10,722     10,722              
Beginning balance, shares (in shares) at Dec. 31, 2022   81,483,600 23,093,860   81,483,600 23,093,860          
Beginning balance at Dec. 31, 2022 (10,740)       $ 815 $ 232     253,737   (265,524)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (16,772)                   (16,772)
Share-based compensation 1,175               1,175    
Change in redemption value of noncontrolling interest 1,104                   1,104
Ending balance, shares (in shares) at Sep. 30, 2023   81,483,600 23,093,860   81,483,600 23,093,860          
Ending balance at Sep. 30, 2023 (25,233)       $ 815 $ 232     254,912   (281,192)
Beginning balance at Jun. 30, 2023       18,879              
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss       (1,886)              
Change in redemption value of noncontrolling interest       (6,271)              
Ending balance at Sep. 30, 2023 10,722     $ 10,722              
Beginning balance, shares (in shares) at Jun. 30, 2023         81,483,600 23,093,860          
Beginning balance at Jun. 30, 2023 (25,283)       $ 815 $ 232     254,479   (280,809)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (6,654)                   (6,654)
Share-based compensation 433               433    
Change in redemption value of noncontrolling interest 6,271                   6,271
Ending balance, shares (in shares) at Sep. 30, 2023   81,483,600 23,093,860   81,483,600 23,093,860          
Ending balance at Sep. 30, 2023 $ (25,233)       $ 815 $ 232     $ 254,912   $ (281,192)